PCSK9 and lung cancer: Additionally, the PCSK9lo group also demonstrated a better objective response rate (ORR) and disease control rate (DCR) compared to the PCSK9hi group (54.4% versus 34.5% and 94.7% versus 65.5%, respectively.356 These results emphasize the need for broader investigations into PCSK9 levels, not only in cancer tissues but also in circulation, with an aim to establish PCSK9 as a potential biomarker for the development, progression, and metastasis of lung cancers.